Comparison of a Blood Self-Collection System with Routine Phlebotomy for SARS-CoV-2 Antibody Testing.

Autor: Wixted D; Duke Clinical and Translational Science Institute, Duke University, Durham, NC 27701, USA., Neighbors CE; Duke Global Health Institute, Duke University, Durham, NC 27710, USA., Pieper CF; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA., Wu A; Department of Clinical Research, Cytel Inc., Waltham, MA 02451, USA.; Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA., Kingsbury C; Duke Clinical and Translational Science Institute, Duke University, Durham, NC 27701, USA., Register H; Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA., Petzold E; Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, NC 27708, USA., Newby LK; Duke Clinical and Translational Science Institute, Duke University, Durham, NC 27701, USA.; Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA.; Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA., Woods CW; Departments of Medicine and Pathology, Duke University Medical Center, Durham, NC 27710, USA.
Jazyk: angličtina
Zdroj: Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2022 Jul 31; Vol. 12 (8). Date of Electronic Publication: 2022 Jul 31.
DOI: 10.3390/diagnostics12081857
Abstrakt: The Coronavirus Disease 2019 (COVID-19) pandemic forced researchers to reconsider in-person assessments due to transmission risk. We conducted a pilot study to evaluate the feasibility of using the Tasso-SST (Tasso, Inc, Seattle, Washington) device for blood self-collection for use in SARS-CoV-2 antibody testing in an ongoing COVID-19 prevalence and immunity research study. 100 participants were recruited between January and March 2021 from a previously identified sub-cohort of the Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study who were under-going bimonthly COVID-19 antibody testing. Participants were given a Tasso-SST kit and asked to self-collect blood during a scheduled visit where trained laboratory personnel performed routine phlebotomy. All participants completed an after-visit survey about their experience. Overall, 70.0% of participants were able to collect an adequate sample for testing using the device. Among those with an adequate sample, there was a high concordance in results between the Tasso-SST and phlebotomy blood collection methods (Cohen’s kappa coefficient = 0.88, Interclass correlation coefficient 0.98 [0.97, 0.99], p < 0.0001). The device received a high-level (90.0%) of acceptance among all participants. Overall, the Tasso-SST could prove to be a valuable tool for seroprevalence testing. However, future studies in larger, diverse populations over longer periods may provide a better understanding of device usability and acceptance among older participants and those with comorbidities in various use scenarios.
Databáze: MEDLINE